A phase I study of oral uracil/ftorafur (UFT) plus leukovorin in combination with weekly paclitaxel (P) in patients (pts) with solid tumors.

被引：0
|
作者：
Mayer, F
von Pawel, J
Beck, J
Schroeder, M
Hartmann, JT
Kanz, L
Bokemeyer, C
机构：
[1] St Johannes Hosp, Duisburg, Germany
[2] Univ Mainz, D-6500 Mainz, Germany
[3] Asklepios Fachklin Munchen Gauling, Munich, Germany
[4] Univ Tubingen, Med Ctr, Dept Hematol Oncol, Tubingen, Germany
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
620P
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [31] Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors
    Ready, Neal E.
    Lipton, Alan
    Zhu, Yali
    Statkevich, Paul
    Frank, Emily
    Curtis, Dolores
    Bukowski, Ronald M.
    CLINICAL CANCER RESEARCH, 2007, 13 (02) : 576 - 583
  • [32] Combination study of navitoclax with gemcitabine (G) in patients (pts) with solid tumors.
    Cleary, J. M.
    Lima, C. M. S. Rocha
    Hurwitz, H.
    Montero, A. J.
    Shapiro, G.
    Franklin, C.
    Yang, J.
    Graham, A. M.
    Busman, T.
    Mabry, M.
    Holen, K. D.
    Krivoshik, A.
    Humerickhouse, R.
    Uronis, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors
    Bekaii-Saab, Tanios S.
    Liu, Jing
    Chan, Kenneth K.
    Balcerzak, Stanley P.
    Ivy, Percy S.
    Grever, Michael R.
    Kraut, Eric H.
    CLINICAL CANCER RESEARCH, 2008, 14 (11) : 3434 - 3440
  • [34] A phase I study of temsirolimus plus erlotinib in patients with refractory solid tumors.
    Wang-Gillam, Andrea
    Tan, Benjamin R.
    Waqar, Saiama Naheed
    Suresh, Rama
    Morgensztern, Daniel
    Van Tine, Brian Andrew
    Nieman, Rebecca
    Govindan, Ramaswamy
    Lockhart, Albert C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Phase I study of gemcitabine plus bortezomib in elderly patients with solid tumors.
    Bommakanti, Satya
    Gada, Purvi
    Dudek, Arkadiusz
    CANCER RESEARCH, 2009, 69
  • [36] A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.
    Puglisi, M.
    van Doorn, L.
    Blanco-Codesido, M.
    De Jonge, M. J.
    Moran, K.
    Yang, J.
    Busman, T.
    Franklin, C.
    Mabry, M.
    Krivoshik, A.
    Humerickhouse, R.
    Molife, L. R.
    Eskens, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors.
    Jones, S. F.
    Plummer, E. R.
    Burris, H. A.
    Razak, A. R.
    Meluch, A. A.
    Bowen, C. J.
    Williams, D. H.
    Hodge, J. P.
    Dar, M. M.
    Calvert, A. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 85S - 85S
  • [38] Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors.
    Hollebecque, Antoine
    Bahleda, Rastislav
    Thery, Jean Christophe
    Faivre, Laura
    Le Deley, Marie-Cecile
    Paci, Angelo
    Varga, Andrea
    Gazzah, Anas
    Massard, Christophe
    Poinsignon, Vianney
    Malekzadeh, Katty
    Ribrag, Vincent
    Angevin, Eric
    Postel-Vinay, Sophie
    Gomez-Roca, Carlos Alberto
    Gharib, Myriam
    Dufour, Fabienne
    Soria, Jean-Charles
    Spano, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer
    Meropol, NJ
    Rustum, YM
    Petrelli, NJ
    RodriguezBigas, M
    Frank, C
    Ho, DH
    Kurowski, M
    Creaven, PJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 37 (06) : 581 - 586
  • [40] UFT in combination with oxaliplatin:: clinical phase I study in patients with advanced or metastatic solid tumors
    Sastre, Javier
    Aranda, Enrique
    Abad, Albert
    Gallego, Javier
    Luis Manzano, Jose
    Gomez, Auxiliadora
    Carrato, Alfredo
    Lopez, Eva
    Diaz-Rubio, Eduardo
    ANTI-CANCER DRUGS, 2006, 17 (04) : 417 - 421
12345